$XRAY

MCKEON BRIAN P purchased $101K of XRAY (indirect holdings)

MCKEON BRIAN P purchased 10,000 indirectly-held shares of DENTSPLY SIRONA Inc. (XRAY) at $10.12 ($0.10M total) on 2026-06-12.

Original reporting
SEC EDGAR · MCKEON BRIAN P
Published Jun 15, 2026, 9:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 15, 2026, 9:09 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$XRAY
Neutral
low confidence
Mentioned
$XRAY
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$XRAYNeutralLow
01

Why it matters

The newest fact is the director’s open-market purchase details (10,000 shares at $10.12) and that it was not under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the buy as mild sentiment, but there is no fundamental catalyst in the text.

03

What to watch

The transaction is indirect and the article provides no context on size versus prior holdings beyond the post-transaction share count.

Relevance 5/10Novelty 6/10Timing: Filed June 15; transaction dated June 12.

Background

The article is an SEC Form 4 insider transaction disclosure for Dentsply Sirona (XRAY).

Company-level read

Ticker impact

$XRAYNeutralLow confidence
Context

Dentsply Sirona director Brian P. McKeon filed an SEC Form 4 showing an open-market purchase of 10,000 XRAY shares at $10.12.

Expected impact

Likely limited near-term impact; any effect would be sentiment-only and small versus broader fundamentals.

Evidence & confidence

The filing is a routine Form 4 transaction with no 10b5-1 plan and no accompanying company news (no earnings, guidance, deal, or regulatory action).

Market effects

No clear sector read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be discretionary or part of personal liquidity planning; without follow-on disclosures, signal quality is low.

Key entities

  • DENTSPLY SIRONA Inc.

    Company whose shares were purchased; insider transaction disclosed on SEC Form 4.

  • MCKEON BRIAN P

    Director who reported an open-market purchase of XRAY shares.

Related articles

$XRAYMedAI 8/10

Why Dentsply Sirona (XRAY) Stock Is Trading Lower Today

Dentsply Sirona (XRAY) shares fell about 7% after the company reported Q2 2026 results. Revenue declined 4.1% to $898 million and topped expectations, while adjusted EPS of $0.52 beat estimates. The stock dropped on a weaker full-year revenue forecast of $3.55 billion at the midpoint, about 1% below consensus.

$XRAYMedAI 8/10

XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales

Dentsply Sirona (XRAY) reported Q2 2026 adjusted EPS of 52 cents, down 1.6% YoY but above the Zacks Consensus estimate of 36 cents. Revenue fell 4.1% to $898 million. Wellspect Healthcare growth helped offset declines in other dental segments. The company kept 2026 net sales guidance at $3.5B-$3.6B and adjusted EPS at $1.40-$1.50.